Coenzyme Q10 in Cardiovascular Medicine: Mechanisms, Clinical Evidence, and Future Integration in Heart Failure and Statin Myopathy.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical evidence without systematic review methodology
PubMed 41521431 · doi:10.1097/CRD.0000000000001135
What was done
This narrative review synthesized the biochemical mechanisms, safety, and clinical evidence regarding coenzyme Q10 (CoQ10) supplementation in cardiovascular disease, with a focus on chronic heart failure with reduced ejection fraction (HFrEF) and statin-associated muscle symptoms.
What was found
No quantitative data, effect sizes, or confidence intervals were reported in the abstract. Qualitatively, trial evidence (including the Q-SYMBIO trial) indicates CoQ10 supplementation improves functional capacity, improves ejection fraction, and reduces major cardiovascular events in HFrEF, whereas evidence for statin-induced myopathy remains mixed and inconsistent across studies.
Why it matters
The paper contextualizes CoQ10 as a potentially beneficial, low-risk adjunctive therapy for advanced HFrEF while clarifying that broad, routine supplementation for statin-associated myopathy is not currently warranted.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic pooling. The abstract omits sample sizes, specific dosages, and quantitative endpoints. Evidence for statin myopathy is discordant across available literature.